Nvidia has returned 700% during the Age of AI, but smaller companies may have more room to run. Pfizer, Tesla, and Kroger are ...

At the same time, Pfizer is searching outside the company for a new head of research and development before its longtime chief scientific officer Mikael Dolsten departs at the end of the year.

Weeks before that, Pfizer announced that Dr. Mikael Dolsten, chief scientific officer and president of Pfizer research and development, would leave the company. The company also hired Andrew Baum, a ...

According to the group’s soon-to-depart chief scientific officer, Mikael Dolsten, Pfizer has a “robust pipeline” of three clinical and several preclinical candidates. While danuglipron has ...

and we will focus our efforts on gathering the data to understand its potential profile," said Pfizer R&D chief scientific officer and president Mikael Dolsten, MD, PhD. AbbVie (NYSE: ABBV ...

It’s the second major change at the top of a big pharma group to be announced this week, after Pfizer’s chief scientific officer and president of R&D, Mikael Dolsten, also announced his ...

As Rocket Pharmaceuticals welcomes Dr. Mikael Dolsten from Pfizer to its Board of Directors, it's valuable to understand the financial health and market position of Pfizer (NYSE: PFE), where Dr.